Friday, 21 Sep 2018

You are here

Trump Blasts Drug Makers on the Price of Drugs

Reuter's reports Friday that President Donald Trump blasted drugmakers and healthcare “middlemen” for making prescription drugs unaffordable for Americans. Nonetheless, many healthcare stocks rose as it became clear the administration had avoided taking aggressive and direct measures to cut drug prices.

Here are many New Sources on this developing story:

Reuters:Trump assails high drug prices, avoids direct hit on industry  https://reut.rs/2IBaFiY

Bloomber: Trump's Unimpressive Plan to Lower Drug Prices  https://bloom.bg/2I8tkmO

Financial Times: Trump blames foreign countries for high drug prices  https://on.ft.com/2IdPe4c

NY Times: 6 Takeaways From Trump’s Plans to Try to Lower Drug Prices https://nyti.ms/2IEieFS

          Trump’s Plan to Lower Drug Prices Diverges From Campaign Promise  https://nyti.ms/2wyN65D

           Trump to Drop Call for Medicare to Negotiate Lower Drug Prices  https://nyti.ms/2wAmGR1

Wall St. Journal: Trump’s Plan to Cut Drug Prices Leaves Industry Relieved https://on.wsj.com/2IDeAf6

NPR:  Trump Drug Pricing 'Blueprint' Could Take Years To Build  https://n.pr/2IyMRw5

 

 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Managing Comorbidity and Poor Drug Responses

Comorbidity is pervasive and complicates medical care in general. It can be a by-product of aging. It may result from drug therapy or an inciting disease process and may be part of the constellation that defines the primary disorder. A growing body of evidence that suggests that comorbidity has a significant dampening effect on drug responsiveness and, adds to poorer outcomes in patients with inflammatory arthritis.

Opioid Aversion is Augmenting Spinal Steroid Injections

As physicians turn away from opioids, are they resorting to options that may also be unsafe?

The New York Times reports that some physicians are using the anti-inflammatory drug, Depo-Medrol, for intraspinal injections to manage painful spinal and perispinal disorders.

Company Payments to Rheumatologists, Specialists Linked to Increased ACTH Prescriptions

Despite its exorbitant price tag and paucity of supportive clinical evidence, ACTH (corticotropin) sales have increased in the United States. A recent JAMA article examined its use by specialists and found that those who prescribe ACTH (including rheumatologists, nephrologists, neurologists) received corticotropin-related payments from the products sole manufacturer, Mallinckrod.

Veterans Administration Shuns Marijuana as an Option

Cannabis therapy is legal in 30 states in the US, and soon to be legal in Canada and Great Britian, but the US Veterans Administration continues to reject medical marijuana as a therapeutic option - even in states where it is approved.

Predictors of Methotrexate Non-Response

New research from a UK study suggests that nonresponse to oral or subcutaneous MTX was seen in 43% and is predicted by seronegativity, higher disease activity measures and higher anxiety scores.